Association of XXXX concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness- @entity195 trial.

@entity1 @entity7302 @entity303 @entity2146 @entity195 @entity1090
@entity1090 has been used to treat behavioral symptoms, such as delusions and @entity2146 , in @entity1 with @entity195 . The relationship between magnitude and variability of @entity1090 and @entity7302 exposure and the relationship with time to discontinuation of the medication were explored. Sixty-five subjects from the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease Trial that received @entity1090 were included in this study. Eighteen subjects completed the study without switching medication (completers on @entity1090 ), whereas 47 discontinued the medication. Those who discontinued were divided into 2 groups according to responsiveness to therapy. Using Cox proportional survival regression analysis, we estimated time to discontinuation and factors associated with treatment discontinuation including age, dose, body mass index, neuropsychiatric inventory baseline score, and average exposure (area under the curve [AUC]) to @entity1090 and @entity7302 . Twenty-four and 17 subjects discontinued therapy because of inadequate therapeutic effect and side effects, respectively (6 subjects were excluded because of missing information about reason for switching or discontinuation). Discontinuation hazards for those with a higher than median AUC of the metabolite were 2.54 (P = 0.029; inadequate and side effect group combined) and 3.48 (P = 0.025; inadequate effect group) times that of those in the lower than median AUC group. None of the other covariates contributed significantly to the switching hazard. @entity1090 metabolite, @entity7302 concentrations, correlated with the risk of switching or discontinuing the medication, suggesting that @entity7302 contributes to adverse events and intolerability in @entity303 @entity1 .
